Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma
Signal Transduction and Targeted Therapy · 28.06.2024 · 9 (1)
DOI: 10.1038/s41392-024-01875-4 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Signal Transduction and Targeted Therapy, online erschienen am 28.06.2024. Verfasst von Yanni Wang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking Universi…. Hauptthemen laut MEDLINE: Afatinib, ErbB Receptors, Esophageal Squamous Cell Carcinoma, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China (National Science Foundation of China), the National Youth Top-Level Talent Support Program (“Ten Thousand Talents Scheme”).
Abstract (Originalsprache)
Epidermal growth factor receptor (EGFR) is reportedly overexpressed in most esophageal squamous cell carcinoma (ESCC) patients, but anti-EGFR treatments offer limited survival benefits. Our preclinical data showed the promising antitumor activity of afatinib in EGFR-overexpressing ESCC. This proof-of-concept, phase II trial assessed the efficacy and safety of afatinib in pretreated metastatic ESCC patients ( n = 41) with EGFR overexpression (NCT03940976). The study met its primary endpoint, with a confirmed objective response rate (ORR) of 39% in 38 efficacy-evaluable patients and a median overall survival of 7.8 months, with a manageable toxicity profile. Transcriptome analysis of pretreatment tumors revealed that neurotrophic receptor tyrosine kinase 2 ( NTRK2) was negatively associated with afatinib sensitivity and might serve as a predictive biomarker, irrespective of EGFR expression. Notably, knocking down or inhibiting NTRK2 sensitized ESCC cells to afatinib treatment. Our study provides novel findings on the molecular factors underlying afatinib resistance and indicates that afatinib has the potential to become an important treatment for metastatic ESCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
- Genecast Biotechnology Co., Ltd, Wuxi, PR China.
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer…
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, China.
- Precision Scientific (Beijing) Co., Ltd., Beijing, China.
- Generulor Company Bio-X Lab, Zhuhai, Guangdong, China.
ORCID-Profile: Jian Li, Tianqi Sun, Henghui Zhang, Lin Shen, Zhihao Lu
Förderung
- National Natural Science Foundation of China (National Science Foundation of China)
- the National Youth Top-Level Talent Support Program (“Ten Thousand Talents Scheme”)
Zitieren
APA
Wang, Y., Liu, C., Chen, H., Jiao, X., Wang, Y., Cao, Y., Li, J., Zhang, X., Sun, Y., Zhuo, N., Dong, F., Gao, M., Wang, F., Dong, L., Gong, J., Sun, T., Zhu, W., Zhang, H., Shen, L., & Lu, Z. (2024). Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma. Signal Transduction and Targeted Therapy, 9(1). https://doi.org/10.1038/s41392-024-01875-4
Vancouver
Wang Y, Liu C, Chen H, Jiao X, Wang Y, Cao Y, et al. Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma. Signal Transduction and Targeted Therapy. 2024;9(1). doi:10.1038/s41392-024-01875-4
BibTeX
@article{Wang2024,
author = {Wang, Yanni and Liu, Chang and Chen, Huan and Jiao, Xi and Wang, Yujiao and Cao, Yanshuo and Li, Jian and Zhang, Xiaotian and Sun, Yu and Zhuo, Na and Dong, Fengxiao and Gao, Mengting and Wang, Fengyuan and Dong, Liyuan and Gong, Jifang and Sun, Tianqi and Zhu, Wei and Zhang, Henghui and Shen, Lin and Lu, Zhihao},
title = {Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma},
journal = {Signal Transduction and Targeted Therapy},
year = {2024},
volume = {9},
number = {1},
doi = {10.1038/s41392-024-01875-4}
}
EUVIMED